Megumi Furuta

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Megumi Furuta, Hidehito Horinouchi, Isao Yokota, Teppei Yamaguchi, Shoichi Itoh, Takafumi Fukui, Akira Iwashima, Jun Sugisaka, Yu Miura, Hisashi Tanaka, Taichi Miyawaki, Hiroshi Yokouchi, Keita Miura, Ryota Saito, Go Saito, Tatsuhiko Kamoshida, Yusuke Uchinami, Tatsuya Kato, Kunihiko Kobayashi, Hajime Asahina
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056). Cancer science (2024)
Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Hidehito Horinouchi, Yuichiro Ohe, Yoshiro Nakahara, Katsuhiko Naoki, Tetsuhiko Asao, Kazuhisa Takahashi, Sho Saeki, Takuro Sakagami, Kazuhisa Nakashima, Yukari Tsubata, Yu Fujita, Kazuyoshi Kuwano, Megumi Furuta, Jun Sakakibara Konishi, Mayu Ohuchi, Yuichi Ando, Hidenori Mizugaki, Akinobu Hamada
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clinical pharmacology and therapeutics (2024)
Hirofumi Takahashi, Jun Sakakibara Konishi, Megumi Furuta, Tetsuaki Shoji, Kosuke Tsuji, Daisuke Morinaga, Eiki Kikuchi, Junko Kikuchi, Takuro Noguchi, Kanako C Hatanaka, Yutaka Hatanaka, Naofumi Shinagawa, Satoshi Konno
Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer. Cancer science (2022)
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression. Cancer science 113 (6) (2022)
Megumi Furuta, Hajime Kikuchi, Tetsuaki Shoji, Yuta Takashima, Eiki Kikuchi, Junko Kikuchi, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Jun Sakakibara-Konishi
DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer science 110 (5) (2019)